您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > VU 0155069
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
VU 0155069
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
VU 0155069图片
CAS NO:1130067-06-9
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍

化学性质

Physical AppearanceWhite solid
StorageStore at -20°C
M.Wt499.43
Cas No.1130067-06-9
FormulaC26H27ClN4O2·HCl
Solubilityinsoluble in EtOH; insoluble in H2O; ≥25.15 mg/mL in DMSO
Chemical Name(S)-N-(1-(4-(5-chloro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-naphthamide hydrochloride
Canonical SMILESClC1=CC=C2N(C(NC2=C1)=O)C3CCN(C[C@H](C)NC(C4=CC=C5C(C=CC=C5)=C4)=O)CC3.Cl
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

VU 0155069 is a selective phospholipase D1 (PLD1) inhibitor, with an IC50 value of 46 nM [1].

PLD1 is one of the main PLD isoforms in mammals. PLD is an important enzyme responsible for the production of the lipid second messenger, i.e. phosphatidic acid which participates in both G protein-coupled receptor and receptor tyrosine kinase signal transduction networks [1]

In Calu-1 and HEK293-gfpPLD2 cells, VU 0155069 blocked both PLD1 and PLD2 activity at the concentration of 20 μM, whilst preferentially inhibited PLD1 at a lower concentration of 200 nM. In 4T1 cells, PLD1-preferring VU 0155069 at 200 nM significantly decreased cell migration compared with the vehicle control [1].

In mice bearing hepatocellular carcinoma xenografts, VU 0155069 (5 mg/kg, 50 μl, s.c., on alternate days) significantly reduced xenograft tumor size and weight. Furthermore, VU 0155069 treatment substantially reduced both proliferating cell nuclear antigen- (PCNA-) and Ki67-positive cell populations in skin xenograft tumors [2].

References:

[1]. Scott S A, Selvy P E, Buck J R, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nature Chemical Biology, 2009, 5(2): 108-117.

[2]. Xiao J, Sun Q, Bei Y, et al. Therapeutic inhibition of phospholipase D1 suppresses hepatocellular carcinoma. Clinical Science, 2016, 130(13): 1125-1136.